Pediatrix Medical Group, Inc. ( (MD) ) has released its Q4 earnings. Here is a breakdown of the information Pediatrix Medical Group, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pediatrix Medical Group, Inc. is a prominent provider of physician services, specializing in maternal-fetal medicine, neonatology, and pediatric subspecialties, with a strong commitment to clinical excellence and research-backed care. Pediatrix Medical Group reported a solid financial performance for the fourth quarter of 2024, with earnings per share of $0.36 and an adjusted EPS of $0.51, reflecting strong operational efficiency and strategic restructuring efforts. Key highlights from the quarter include net revenue of $502 million, a net income of $30 million, and an adjusted EBITDA of $69 million, underscoring the company’s successful portfolio restructuring and cost management strategies. The company also noted a significant year-over-year increase in same-unit revenue due to improved reimbursement and patient volume growth, alongside a reduction in practice salaries and benefits expenses. Looking ahead, Pediatrix Medical Group remains focused on optimizing its operations and strengthening relationships with hospitals and health systems, anticipating an adjusted EBITDA range of $215 million to $235 million for 2025, indicating a cautiously optimistic outlook for continued growth and operational efficiency.
